We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced...
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective...
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2...
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC – 4 mg dose demonstrated 3 of 3 patients...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion...
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1724 | -3.72354211663 | 4.63 | 5.15 | 3.97 | 62017 | 4.32657499 | CS |
| 4 | -0.7224 | -13.9459459459 | 5.18 | 5.47 | 3.97 | 67456 | 4.74587448 | CS |
| 12 | -1.3324 | -23.01208981 | 5.79 | 6.04 | 3.97 | 46707 | 5.19671242 | CS |
| 26 | -4.8624 | -52.1716738197 | 9.32 | 10.42 | 3.97 | 44281 | 6.74468116 | CS |
| 52 | -0.5724 | -11.37972167 | 5.03 | 10.42 | 3.32 | 49840 | 6.99767127 | CS |
| 156 | -9.3424 | -67.6985507246 | 13.8 | 16.24 | 3.32 | 50383 | 7.00063122 | CS |
| 260 | -9.3424 | -67.6985507246 | 13.8 | 16.24 | 3.32 | 50383 | 7.00063122 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
